InduPro's platform maps protein organization on the cell surface. This understanding of proximity allows better prediction of which bispecific pairings will yield enhanced therapeutic effects, a critical flaw in approaches that only consider co-expression.
The key attraction to InduPro wasn't just its novel science for predicting target pairs, but its integrated capability to build molecules based on those predictions. This fusion of a predictive engine and in-house biologics expertise creates a significant competitive moat.
Resisting the overused "platform" buzzword, the CEO argues a true platform is merely the foundation. Its success is measured by its ability to consistently produce a pipeline of differentiated therapeutics for patients, not by the elegance of its technology alone.
The most meaningful validation for InduPro wasn't just VC funding, but discovering in partnership talks that large pharmas had their own internal proximity biology efforts. This confirmed market need and validated InduPro's differentiated approach to a known, difficult problem.
InduPro's AI advantage isn't a better algorithm but a superior, proprietary dataset generated in-house. This high-quality data, combining proximity maps with protein quantification, is the true differentiator that their tailor-made AI tools interrogate, avoiding reliance on public data.
Acknowledging that China's development speed for known targets is "unparalleled," the CEO's strategy is not to match it. Instead, the competitive edge comes from the innovative front-end: discovering novel target pairings from a proprietary platform that others cannot.
InduPro's capital efficiency model is clear: keep core, differentiating work like proprietary database creation and initial molecule screening internal. Outsource scalable, less-differentiated activities like large-scale manufacturing and multi-site clinical trials to specialized CROs.